Avalo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Doyle Mittie
Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Doyle Mittie
Avalo Therapeutics | 8-K: Current report
Avalo Therapeutics | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)
Avalo Therapeutics | 10-Q/A: Quarterly report (Amendment)
Avalo Therapeutics | 8-K: Current report
Avalo Therapeutics | ARS: Annual Report to Security Holders
Avalo Therapeutics | DEFA14A: Others
Avalo Therapeutics | DEF 14A: Definitive information statements
Avalo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer VARKI PAUL
Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer VARKI PAUL
Avalo Therapeutics | 8-K: Current report
Avalo Therapeutics | 8-K/A: Current report (Amendment)
Avalo Therapeutics | 8-K: Current report
Avalo Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Avalo Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Avalo Therapeutics | 8-K/A: Current report (Amendment)
Avalo Therapeutics | 8-K: Current report
Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Allostery Master Fund LP(7.6%),Allostery Investments LP(7.6%), etc.
Avalo Therapeutics | 10-Q: Quarterly report
No Data